As of May 31, 2025, Dexcom Inc (DXCM) reports a EV/EBITDA of 42.07.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Dexcom Inc's EV/EBITDA to Peers
To better understand Dexcom Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Dexcom Inc (DXCM) | 42.07 |
| Penumbra Inc (PEN) | 167.93 |
| ABIOMED Inc (ABMD) | 89.47 |
| Shockwave Medical Inc (SWAV) | 67.85 |
| Insulet Corp (PODD) | 60.70 |
| STERIS plc (STE) | 28.71 |
Compared to its competitors, Dexcom Inc's EV/EBITDA is among the highest compared to peers, suggesting the market values the company at a premium, possibly due to growth expectations.